Summary
- Bristol Myers Squibb has performed incredibly well recently, integrating its Celgene acquisition.
- The company's top drugs face patent threats, but the company has continued to defend these patent threats.
- The company faces the risk of low revenue visibility without continued R&D investments, however, as Celgene is paid down we expect shareholder returns to grow.
- I do much more than just articles at The Energy Forum: Members get access to model portfolios, regular updates, a chat room, and more. Get started today ยป
Bristol Myers Squibb (NYSE: BMY) is one of the largest biotech companies in the world with a market capitalization of near $140 billion. The company's enormous size comes from its acquisition of Celgene, with the company's net enterprise value now more than $160 billion. Combining all of this together, we can see this company's impressive and growing potential to reward shareholders.
Bristol Myers Squibb 2Q 2020 Results
Bristol Myers Squibb had impressive 2Q 2020 results that highlight the strength of the company's portfolio.
Bristol Myers Squibb 2Q Results - Bristol Myers Squibb Investor Presentation
Bristol Myers Squibb had incredibly impressive results with $10.1 billion in 2Q 2020 sales, working down a $350 million inventory work down from the company's 1Q COVID-19 build. The company is continuing to progress its pipeline with strong submissions across its top of the line products. The company had several launches and is working to support its largest projects.
